Galectin Therapeutics Inc Stock Price, News & Analysis

Galectin Therapeutics Inc. (NASDAQ: GALT) reported a fiscal 2020 net loss of $23.6 million, or $0.41 per share, up from a loss of $20.2 million in 2019. The increase in losses was primarily due to higher research and development costs, particularly for the NAVIGATE clinical trial. The Company has $27.1 million in cash and expects additional funding needs of approximately $45-$50 million to advance the NAVIGATE trial through its upcoming interim analysis in late 2023. CEO Joel Lewis expressed optimism about ongoing studies and organizational improvements.

Galectin Therapeutics (NASDAQ:GALT) announced significant findings published in OncoImmunology regarding belapectin, a galectin-3 inhibitor. Research showed that belapectin combined with an anti-OX40 antibody effectively reduces tumor progression, enhancing survival in tumor-bearing mice. This validates ongoing clinical trials combining belapectin with pembrolizumab (Keytruda), indicating potential to improve cancer treatment. Additionally, belapectin is under investigation for treating NASH cirrhosis, highlighting its dual focus on oncology and liver diseases.

Galectin Therapeutics (NASDAQ:GALT) announced that Dr. Pol Boudes, M.D., the Chief Medical Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be accessible on-demand from March 9 at 7:00 am (EST) and will be archived for 90 days. The company focuses on developing therapies for chronic liver disease and cancer, with its lead drug, belapectin, targeting galectin-3, significant in inflammatory and malignant diseases, and holds FDA Fast Track designation.

Galectin Therapeutics (NASDAQ:GALT) announced that Dr. Pol F. Boudes, Chief Medical Officer, will present on Belapectin, a galectin-3 inhibitor in Phase 2b/3 for treating NASH cirrhosis, at the 4th Annual Digital NASH Summit on December 17, 2020, at 09:00 AM EST.

Belapectin targets galectin-3, a protein linked to liver diseases. Preclinical studies indicate its potential to reverse liver fibrosis and cirrhosis, with encouraging results from the NASH-CX clinical trial.

Galectin Therapeutics (NASDAQ:GALT) announced a successful 2020 Annual Meeting, where management updates highlighted clinical trials for belapectin, targeting cirrhosis. The transition in management was seamless, according to Chairman Dick Uihlein. CEO Joel Lewis emphasized the importance of data from a pharmacokinetic study for future research. Chief Medical Officer Pol Boudes discussed a promising combination therapy trial with Keytruda. The company aims to address non-alcoholic steatohepatitis (NASH), a significant liver condition affecting millions.

Galectin Therapeutics Inc. (NASDAQ:GALT) will present a corporate update during its 2020 Annual Meeting of Stockholders on December 3, 2020, at 11:00 a.m. EST. This live webcast follows the business portion of the meeting and can be accessed online. The company focuses on developing therapies for chronic liver disease and cancer, with its lead drug, belapectin, targeting galectin-3 protein involved in various inflammatory and malignant diseases. Belapectin has received Fast Track designation for NASH cirrhosis by the FDA. Additional programs are underway in immunotherapy for advanced melanoma.

Galectin Therapeutics (NASDAQ: GALT) initiated its Phase 2b/3 NASH-RX trial targeting NASH cirrhosis, aiming to address a critical medical need. CEO Joel Lewis highlighted the trial's unique position as one of the few late-stage studies in this field. The first patient was enrolled in August 2020, with plans for global patient inclusion. Key appointments to the board, including Richard Zordani and Dr. Elissa Schwartz, aim to enhance financial and clinical expertise. The company also continues its commitment to the development of belapectin, a galectin-3 inhibitor, with potential applications beyond NASH cirrhosis.

Galectin Therapeutics (NASDAQ:GALT) announced an investor conference call to discuss its NASH-RX clinical trial and introduce new CEO Joel Lewis. The event is set for September 29, 2020, at 4:00 p.m. EDT, accessible via a dedicated phone line or webcast. The company aims to develop therapies for chronic liver disease and cancer, with its lead drug belapectin showing promise in treating NASH with cirrhosis. The press release also included forward-looking statements regarding the potential success of ongoing clinical programs and the challenges ahead.

Galectin Therapeutics (NASDAQ:GALT) announced its participation in the H.C. Wainwright 22nd Annual Virtual Global Investment Conference on September 14, 2020. Management will present at 12:30 p.m. EDT and provide a live webcast accessible via the conference website or the company's own site. Additionally, one-on-one meetings with investors will be available throughout the conference, which runs from September 14 - 16, 2020. Galectin focuses on developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3.